Puma Biotechnology Inc expected to post earnings of 30 cents a share - Earnings Preview

Puma Biotechnology

27/02/2024 21:27

* Puma Biotechnology Inc  PBYI.OQ   PBYI.O  is expected
to show a
rise in quarterly revenue when it reports  results on February
29 for the period ending December 31 2023
    * The Los Angeles California-based  company is expected to
report
a 11.9% increase in revenue to $73.55 million from $65.7 million
a year ago, according to the mean estimate from 2 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Puma Biotechnology Inc
is for
earnings of 30 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Puma
Biotechnology Inc is $4.00​, below​ its last closing price
of $6.48. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  0.08        0.08       0.12      Beat    56.5
 Jun. 30 2023  0.01        0.01       0.05      Beat    566.7
 Mar. 31 2023  -0.07       -0.07      0.03      Beat    142.9​
 Dec. 31 2022  0.05        0.05       -0.12     Missed  -340
 ​​Sep.        -0.06       -0.05      -0.01     Beat    81.8
 30 2022                                                
 Jun. 30 2022  0.01        0.01       0.21      Beat    1,958.
                                                        8​
 Mar. 31 2022  -0.16       -0.17      -0.08     Beat    51.8
 Dec. 31 2021  -0.08       -0.09      0.10      Beat    214.2
 This summary was machine generated February 27 at 21:27 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)